Skip to main content
Article thumbnail
Location of Repository

Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation

By P.J. de Pagter, R. Schuurman, Ellen Meijer, D. van Baarle, E.A.M. Sanders and J.J. Boelens


Human herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stem cell transplantation\ud (HSCT) and has been suggested to be associated with increased mortality and severe clinical manifestations,\ud including graft versus host disease (GvHD). The exact etiological role of HHV6 reactivation in\ud increased morbidity and mortality after HSCT remains unclear. This review will focus on the current\ud available evidence of HHV6 reactivation after HSCT and its immuno-modulatory capacities, with particular\ud emphasis on the severe complication GvHD. At present, no effective specific antiviral treatment for\ud HHV6 reactivation has been identified. The currently available antiviral agents are outlined, aswell as possible\ud future strategies for the treatment of HHV6 reactivation. Non-toxic, specific treatment or prevention\ud of HHV6 reactivation might improve the safety and efficacy of the HSCT procedure

Topics: Geneeskunde, Viral reactivation, HHV-6, Graft versus host disease, Hematopoietic stem cell transplantation, Immunology
Year: 2008
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.